BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
Clinical trial NCT07258680 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07258680
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-10-01
- Primary completion
- 2028-12-01
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.